These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19019675)

  • 1. Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
    Tecle H; Shao J; Li Y; Kothe M; Kazmirski S; Penzotti J; Ding YH; Ohren J; Moshinsky D; Coli R; Jhawar N; Bora E; Jacques-O'Hagan S; Wu J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):226-9. PubMed ID: 19019675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors.
    Buchstaller HP; Burgdorf L; Finsinger D; Stieber F; Sirrenberg C; Amendt C; Grell M; Zenke F; Krier M
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2264-9. PubMed ID: 21420298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
    Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.
    Cao J; Gao H; Bemis G; Salituro F; Ledeboer M; Harrington E; Wilke S; Taslimi P; Pazhanisamy S; Xie X; Jacobs M; Green J
    Bioorg Med Chem Lett; 2009 May; 19(10):2891-5. PubMed ID: 19361991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives.
    Melagraki G; Afantitis A; Sarimveis H; Igglessi-Markopoulou O; Koutentis PA; Kollias G
    Chem Biol Drug Des; 2010 Nov; 76(5):397-406. PubMed ID: 20925691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
    Akritopoulou-Zanze I; Hajduk PJ
    Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolopyridazine MEK inhibitors.
    Chen Z; Kim SH; Barbosa SA; Huynh T; Tortolani DR; Leavitt KJ; Wei DD; Manne V; Ricca CS; Gullo-Brown J; Poss MA; Vaccaro W; Salvati ME
    Bioorg Med Chem Lett; 2006 Feb; 16(3):628-32. PubMed ID: 16275076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
    ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.
    Karcher SC; Laufer SA
    J Med Chem; 2009 Mar; 52(6):1778-82. PubMed ID: 19253982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
    Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
    J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doing more than just the structure-structural genomics in kinase drug discovery.
    Marsden BD; Knapp S
    Curr Opin Chem Biol; 2008 Feb; 12(1):40-5. PubMed ID: 18267130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
    Hartung IV; Hammer S; Hitchcock M; Neuhaus R; Scholz A; Siemeister G; Bohlmann R; Hillig RC; Pühler F
    Bioorg Med Chem Lett; 2016 Jan; 26(1):186-93. PubMed ID: 26611920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.
    Liao JJ
    J Med Chem; 2007 Feb; 50(3):409-24. PubMed ID: 17266192
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
    Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
    Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'retro-design' concept for novel kinase inhibitors.
    Müller G; Sennhenn PC; Woodcock T; Neumann L
    IDrugs; 2010 Jul; 13(7):457-66. PubMed ID: 20582870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors.
    Wityak J; Hobbs FW; Gardner DS; Santella JB; Petraitis JJ; Sun JH; Favata MF; Daulerio AJ; Horiuchi KY; Copeland RA; Scherle PA; Jaffe BD; Trzaskos JM; Magolda RL; Trainor GL; Duncia JV
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1483-6. PubMed ID: 15006386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovering new MAP kinase inhibitors.
    Shapiro P
    Chem Biol; 2006 Aug; 13(8):807-9. PubMed ID: 16931329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.